JP2024529930A5 - - Google Patents
Info
- Publication number
- JP2024529930A5 JP2024529930A5 JP2024503797A JP2024503797A JP2024529930A5 JP 2024529930 A5 JP2024529930 A5 JP 2024529930A5 JP 2024503797 A JP2024503797 A JP 2024503797A JP 2024503797 A JP2024503797 A JP 2024503797A JP 2024529930 A5 JP2024529930 A5 JP 2024529930A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- interfering rna
- sirna molecule
- modified sirna
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/107862 | 2021-07-22 | ||
| CN2021107862 | 2021-07-22 | ||
| PCT/CN2022/107028 WO2023001234A1 (en) | 2021-07-22 | 2022-07-21 | Modified small interfering rna molecules with reduced off-target effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529930A JP2024529930A (ja) | 2024-08-14 |
| JP2024529930A5 true JP2024529930A5 (enExample) | 2025-07-30 |
Family
ID=84979733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503797A Pending JP2024529930A (ja) | 2021-07-22 | 2022-07-21 | 低減されたオフターゲット効果を有する修飾低分子干渉ｒｎａ分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240425853A1 (enExample) |
| EP (1) | EP4373932A4 (enExample) |
| JP (1) | JP2024529930A (enExample) |
| KR (1) | KR20240042457A (enExample) |
| CN (1) | CN118202046A (enExample) |
| CA (1) | CA3227144A1 (enExample) |
| WO (1) | WO2023001234A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080188430A1 (en) * | 2001-05-18 | 2008-08-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| EP1608733B1 (en) * | 2003-04-02 | 2011-12-07 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
| WO2005035759A2 (en) * | 2003-08-20 | 2005-04-21 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20070218551A1 (en) * | 2003-10-02 | 2007-09-20 | Chuan-Yuan Li | Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy |
| TW200731980A (en) * | 2005-12-29 | 2007-09-01 | Alcon Mfg Ltd | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
| EP3121281B1 (en) * | 2007-08-27 | 2021-03-31 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
| EP3929293A3 (en) * | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| CN106117289B (zh) * | 2016-06-24 | 2019-02-12 | 郑州大学 | 2’-o-moe-3’-h-硫代磷酸酯核苷单体及其合成方法 |
| WO2018098328A1 (en) * | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| EP3946369A4 (en) * | 2019-03-26 | 2023-10-18 | University Of Massachusetts | MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY |
| CN110540990B (zh) * | 2019-07-16 | 2024-08-20 | 武汉泽智生物医药有限公司 | 沉默小眼畸形转录因子mRNA表达的siRNA分子 |
-
2022
- 2022-07-21 US US18/580,688 patent/US20240425853A1/en active Pending
- 2022-07-21 WO PCT/CN2022/107028 patent/WO2023001234A1/en not_active Ceased
- 2022-07-21 EP EP22845398.1A patent/EP4373932A4/en active Pending
- 2022-07-21 CA CA3227144A patent/CA3227144A1/en active Pending
- 2022-07-21 JP JP2024503797A patent/JP2024529930A/ja active Pending
- 2022-07-21 KR KR1020247006025A patent/KR20240042457A/ko active Pending
- 2022-07-21 CN CN202280051993.8A patent/CN118202046A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108350454B (zh) | 等位基因选择性基因编辑及其用途 | |
| JP6141018B2 (ja) | 炎症性障害を治療するための分子 | |
| JP2022502055A5 (enExample) | ||
| JP6158833B2 (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
| JP2008510489A (ja) | 多重ｒｎａポリメラーゼｉｉｉプロモーター発現構築物 | |
| WO2019196887A1 (zh) | 一种新型小激活rna | |
| Imbert et al. | Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington's disease | |
| JP2012528588A (ja) | 単一またはマルチ標的遺伝子を抑制するマルチ−シストロンｓｈＲＮＡ発現カセット | |
| CN113249380B (zh) | 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用 | |
| CN102782133A (zh) | 抑制c-Met表达的siRNA及含有所述siRNA的抗癌组合物 | |
| CN105073141A (zh) | 用于将基因递送到细胞的功能化dna树状聚合物 | |
| CN107365785A (zh) | 一种调控细胞内NF‑κB活性的基因表达载体及其调控方法和应用 | |
| WO2022062440A1 (zh) | 靶向CTGF基因的gRNA及其应用 | |
| CN101981188B (zh) | 作为抗疟剂的rna适体的筛选 | |
| JP2007512847A5 (enExample) | ||
| JPWO2004078974A1 (ja) | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
| CN109477110B (zh) | 抑制mex3b基因的表达的核酸、试剂、及疾病的预防或治疗剂 | |
| KR20240040112A (ko) | 방법 | |
| WO2012139628A1 (en) | Coding polypurine hairpins for the treatment of cancer | |
| WO2025007951A1 (zh) | 一种靶向ttr的sacas9 sgrna及其修饰方式 | |
| JP2022531580A (ja) | ベクターでの使用のためのマルチプレックス化ｓｈＲＮＡ | |
| JP2024028895A (ja) | オリゴヌクレオチド分子及び腫瘍治療におけるその応用 | |
| JP2024525078A5 (enExample) | ||
| CN101189343B (zh) | 多rna聚合酶ⅲ启动子表达构建体 | |
| JP2024513131A (ja) | オリゴヌクレオチド |